Blood Test Biomarkers Diagnose Autism Accurately
By LabMedica International staff writers Posted on 08 Mar 2018 |

Image: The Acquity UPLC system with a Xevo-TQS tandem mass spectrometer (Photo courtesy of Waters).
Autism spectrum disorder (ASD) is a condition that impacts cognition, behavior and social interaction, causing a wide spectrum of other disabilities, such as speech disturbances, repetitive and/or compulsive behaviors, hyperactivity, anxiety and difficulty to adapt to new environments.
Given its developmental nature, ASD may have an early onset, but it typically takes a while for the first symptoms to appear. As such, early diagnosis is not usually possible. Therefore, a chemistry-based diagnosis test for the early detection of ASD may be crucial, enabling children to receive the care that they need much earlier on, but until now, no such test was available.
An international team of scientists led by those at the University of Warwick (Coventry, UK) recruited 38 children with ASD (29 male, nine female; age 7.6 ± 2.0 years) and 31 age-matched healthy controls (23 males, eight females; 8.6 ± 2.0 years). Blood was withdrawn in the morning from fasting children. Spot urine samples were the first ones in the morning. Blood samples were collected using ethylenediaminetetra-acetic acid as anticoagulant. Plasma and blood cells were separated immediately by centrifugation (2000g, 10 minutes) and plasma samples stored at − 80 °C until analysis.
The content of glycated, oxidized, and nitrated adduct residues in plasma protein was quantified in exhaustive enzymatic digests by stable isotopic dilution analysis liquid chromatography-tandem mass spectrometry (LC-MS/MS, Acquity UPLC system with a Xevo-TQS tandem mass spectrometer; Waters, Manchester, UK; www.waters.com), with correction for autohydrolysis of hydrolytic enzymes. Machine learning methods were then employed to explore and optimize combinations of analyte data for ASD diagnosis.
The team found that children with ASD had increased advanced glycation end products (AGEs), Nε-carboxymethyl-lysine (CML) and Nω-carboxymethylarginine (CMA), and increased oxidation damage marker, dityrosine (DT), in plasma protein, with respect to healthy controls. Theye also found that children with ASD had increased CMA free adduct in plasma ultrafiltrate and increased urinary excretion of oxidation free adducts, alpha-aminoadipic semialdehyde and glutamic semialdehyde. The children with ASD had decreased renal clearance of arginine and CMA with respect to healthy controls. The sensitivity, specificity and receiver-operating characteristic area-under-the-curve were 92%, 84%, and 0.94, respectively. The study was published on February 19, 2018, in the journal Molecular Autism.
Given its developmental nature, ASD may have an early onset, but it typically takes a while for the first symptoms to appear. As such, early diagnosis is not usually possible. Therefore, a chemistry-based diagnosis test for the early detection of ASD may be crucial, enabling children to receive the care that they need much earlier on, but until now, no such test was available.
An international team of scientists led by those at the University of Warwick (Coventry, UK) recruited 38 children with ASD (29 male, nine female; age 7.6 ± 2.0 years) and 31 age-matched healthy controls (23 males, eight females; 8.6 ± 2.0 years). Blood was withdrawn in the morning from fasting children. Spot urine samples were the first ones in the morning. Blood samples were collected using ethylenediaminetetra-acetic acid as anticoagulant. Plasma and blood cells were separated immediately by centrifugation (2000g, 10 minutes) and plasma samples stored at − 80 °C until analysis.
The content of glycated, oxidized, and nitrated adduct residues in plasma protein was quantified in exhaustive enzymatic digests by stable isotopic dilution analysis liquid chromatography-tandem mass spectrometry (LC-MS/MS, Acquity UPLC system with a Xevo-TQS tandem mass spectrometer; Waters, Manchester, UK; www.waters.com), with correction for autohydrolysis of hydrolytic enzymes. Machine learning methods were then employed to explore and optimize combinations of analyte data for ASD diagnosis.
The team found that children with ASD had increased advanced glycation end products (AGEs), Nε-carboxymethyl-lysine (CML) and Nω-carboxymethylarginine (CMA), and increased oxidation damage marker, dityrosine (DT), in plasma protein, with respect to healthy controls. Theye also found that children with ASD had increased CMA free adduct in plasma ultrafiltrate and increased urinary excretion of oxidation free adducts, alpha-aminoadipic semialdehyde and glutamic semialdehyde. The children with ASD had decreased renal clearance of arginine and CMA with respect to healthy controls. The sensitivity, specificity and receiver-operating characteristic area-under-the-curve were 92%, 84%, and 0.94, respectively. The study was published on February 19, 2018, in the journal Molecular Autism.
Latest Clinical Chem. News
- AI-Powered Blood Test Accurately Detects Ovarian Cancer
- Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
Channels
Molecular Diagnostics
view channel
POC Diagnostic Platform Combines Immunoassay and Molecular Testing
An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design.... Read more
Single Blood Test Could Detect Different Types of Cancer at Early Stages
Currently, reliable screening for only a few types of cancer is available, such as those affecting the breast, bowel, cervix (neck of the womb), and lung for individuals at high risk. While these screenings... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more